129 related articles for article (PubMed ID: 32126359)
1. pH-Sensitive chitosan-tripolyphosphate nanoparticles increase doxorubicin-induced growth inhibition of cervical HeLa tumor cells by apoptosis and cell cycle modulation.
Nogueira-Librelotto DR; Scheeren LE; Macedo LB; Vinardell MP; Rolim CMB
Colloids Surf B Biointerfaces; 2020 Jun; 190():110897. PubMed ID: 32126359
[TBL] [Abstract][Full Text] [Related]
2. Chitosan-tripolyphosphate nanoparticles functionalized with a pH-responsive amphiphile improved the in vitro antineoplastic effects of doxorubicin.
Nogueira-Librelotto DR; Scheeren LE; Vinardell MP; Mitjans M; Rolim CMB
Colloids Surf B Biointerfaces; 2016 Nov; 147():326-335. PubMed ID: 27543694
[TBL] [Abstract][Full Text] [Related]
3. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
[TBL] [Abstract][Full Text] [Related]
4. In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles.
Nogueira DR; Tavano L; Mitjans M; Pérez L; Infante MR; Vinardell MP
Biomaterials; 2013 Apr; 34(11):2758-72. PubMed ID: 23352041
[TBL] [Abstract][Full Text] [Related]
5. Inclusion of a pH-responsive amino acid-based amphiphile in methotrexate-loaded chitosan nanoparticles as a delivery strategy in cancer therapy.
Nogueira DR; Scheeren LE; Macedo LB; Marcolino AI; Pilar Vinardell M; Mitjans M; Rosa Infante M; Farooqi AA; Rolim CM
Amino Acids; 2016 Jan; 48(1):157-68. PubMed ID: 26306845
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells.
Scheeren LE; Nogueira-Librelotto DR; Mathes D; Pillat MM; Macedo LB; Mitjans M; Vinardell MP; Rolim CMB
Toxicol In Vitro; 2021 Sep; 75():105192. PubMed ID: 33984456
[TBL] [Abstract][Full Text] [Related]
7. Stepwise dual pH and redox-responsive cross-linked polypeptide nanoparticles for enhanced cellular uptake and effective cancer therapy.
Qu J; Wang R; Peng S; Shi M; Yang ST; Luo JB; Lin J; Zhou QH
J Mater Chem B; 2019 Dec; 7(45):7129-7140. PubMed ID: 31663585
[TBL] [Abstract][Full Text] [Related]
8. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
9. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.
Chen WL; Yang SD; Li F; Qu CX; Liu Y; Wang Y; Wang DD; Zhang XN
Acta Biomater; 2018 Nov; 81():219-230. PubMed ID: 30267887
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles incorporating pH-responsive surfactants as a viable approach to improve the intracellular drug delivery.
Nogueira DR; Scheeren LE; Pilar Vinardell M; Mitjans M; Rosa Infante M; Rolim CM
Mater Sci Eng C Mater Biol Appl; 2015 Dec; 57():100-6. PubMed ID: 26354244
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor drug delivery system based on cyclodextrin-containing pH-responsive star polymer: in vitro and in vivo evaluation.
Xiong Q; Zhang M; Zhang Z; Shen W; Liu L; Zhang Q
Int J Pharm; 2014 Oct; 474(1-2):232-40. PubMed ID: 25149124
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway.
Ye BL; Zheng R; Ruan XJ; Zheng ZH; Cai HJ
Biochem Biophys Res Commun; 2018 Jan; 495(1):414-420. PubMed ID: 29097204
[TBL] [Abstract][Full Text] [Related]
14. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
[TBL] [Abstract][Full Text] [Related]
15. pH-sensitive amphiphilic chitosan-quercetin conjugate for intracellular delivery of doxorubicin enhancement.
Mu Y; Wu G; Su C; Dong Y; Zhang K; Li J; Sun X; Li Y; Chen X; Feng C
Carbohydr Polym; 2019 Nov; 223():115072. PubMed ID: 31427010
[TBL] [Abstract][Full Text] [Related]
16. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
[TBL] [Abstract][Full Text] [Related]
17. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
Eivazi N; Rahmani R; Paknejad M
Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
[TBL] [Abstract][Full Text] [Related]
18. Preparation of collagen peptide functionalized chitosan nanoparticles by ionic gelation method: An effective carrier system for encapsulation and release of doxorubicin for cancer drug delivery.
Anandhakumar S; Krishnamoorthy G; Ramkumar KM; Raichur AM
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):378-385. PubMed ID: 27770906
[TBL] [Abstract][Full Text] [Related]
19. Design Graph Theoretical Analysis and
Kunjiappan S; Panneerselvam T; Somasundaram B; Sankaranarayanan M; Parasuraman P; Joshi SD; Arunachalam S; Murugan I
Anticancer Agents Med Chem; 2018; 18(13):1900-1918. PubMed ID: 29956638
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
